Long term observational study on the therapeutic management of knee osteoarthritis by general practitioners

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"1. Males or females 50 years or older suffering from symptomatic osteoarthritis of the knee 2. Not treated over the last 6 months for this pathology (non-pharmaceutical treatments and self-medication by analgesics or NSAIDs at low doses will be allowed). 3. For whom the physician will have decided to initiate a first-line treatment in line with the recommendations of EULAR 2000-2003 (paracetamol - systematically taken at a dose of 3 to 4g/d - as pharmacological monotherapy in combination with non-pharmaceutical treatments).","clusion_E":""}